Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

F-star GMBH

Division of f-star GMBH
www.f-star.com

Latest From F-star GMBH

Deals Shaping The Medical Industry, July 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.

Deals BioPharmaceutical

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Deals M & A

F-star Option Deal With Merck On Bispecific IO Antibodies

'Asset-centric' bispecific antibody developer F-star has agreed an option deal for a package of immuno-oncology-focused antibodies with Merck of Germany.

Deals Cancer

Up Front Or Back End? Considering The Best Structure For Milestone Fees

PwC partner Dmitri Drone explained that a deal for an asset with high commercial expectations is best structured with more emphasis on pre-approval than post-approval payments. A post-approval focus on shared risk is more appropriate when an asset is licensed at an earlier stage of development.

Business Strategies Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • f-star Biotechnology Research & Development Co.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Austria
  • Parent & Subsidiaries
  • f-star GMBH
  • F-star GMBH
  • Senior Management
  • John Haurum, PhD, CEO
    Tolga Hassan, CFO
    Jane Dancer, PhD, CBO
    Neil Brewis, PhD, CSO
  • Contact Info
  • F-star GMBH
    Phone: (43) 72055 4215
    Schwarzenbergplatz 7
    Vienna, A-1030
    Austria
Advertisement
Advertisement
UsernamePublicRestriction

Register